

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:  
**USHMR2037 US DIV 1**

Applicants:  
**Ronald Charles Bernotas, et al**

Serial No.  
**10/760,515**

Filing Date:  
**January 20, 2004**

Title of Invention:


**A Method For The Isolation Of Sulfuric Acid Mono- [3.({1-[2-(4-Fluorophenyl)-Ethyl]-Piperidin-4-yl}-Hydroxy-Methyl)-2-Methoxy-Phenyl] Ester**

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at (703) 746-9195, on

Date of Deposit: **June 3, 2004**

Printed Name of Person Signing Certificate: **Maribel Mendez**

Signature: 

Total Number of Pages Sent: **4**

Attorney: **Balaram Gupta**

Group Art Unit: **1625**

Examiner: **Not Yet Assigned**

TO: Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |  |   |
|--|---|
| <input type="checkbox"/> Amendment, 37 CFR _____               | <input type="checkbox"/> Fee Transmittal  |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR _____  |
| <input type="checkbox"/> Extension of Time Petition            | <input checked="" type="checkbox"/> Other <u>Copy of Filing Receipt (2 pgs.)</u>              |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Request for Corrected Filing Receipt (1 pg.)</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal           |   |

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
 NOTICE: The documents accompanying this telex/copy transmission are intended only for the use of the individual or entity named above. If you have received this telex/copy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
Ronald Charles Bernotas, et al

Application No.: 10/760,515

Filed: January 20, 2004

Title: A Method For The Isolation Of Sulfuric Acid Mono-[3-({1-[2-(4-Fluorophenyl)-Ethyl]-Piperidin-4-yl}-Hydroxy-Methyl)-2-Methoxy-Phenyl] Ester

Examiner: Not Yet Assigned

Art Unit: 1625

<b>CERTIFICATE OF TRANSMISSION</b>	
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at (703) 746-9195, on <u>6-3-04</u>	
Date of Deposit	<u>6-3-04</u>
Printed Name of Person Signing Certificate <u>Maribel Mendez</u>	
Signature <u>Maribel Mendez</u>	

**REQUEST FOR CORRECTED FILING RECEIPT**

Mail Stop  
Commissioner of Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the above-identified application, for which issuance of a corrected filing receipt is respectfully requested. There are some errors in the Title reading,

"Method for the isolation of sulfuric acid mono- [3({1-[2-(4-fluorophenyl)-ethyl]-piperidin-4-yl}-2-methoxy-phenyl}ester";

and should read as:

**-A Method For The Isolation Of Sulfuric Acid Mono- [3-({1-[2-(4-Fluorophenyl)-Ethyl]-Piperidin-4-yl}-Hydroxy-Methyl)-2-Methoxy-Phenyl] Ester--**

The Commissioner is hereby authorized to charge any fees, which are required by this paper to Deposit Account 18-1982.

Respectfully submitted,


*Balaram Gupta*  
Balaram Gupta, Reg. No. 40,009  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3364  
Telefax (908) 231-2626  
Aventis Docket No. USHMR2037 US DIV 1



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Albuquerque, New Mexico 87143-1450  
www.uspto.gov



APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/760,515	01/20/2004	1625	770	USHMR2037 US DIV 1		4	1

CONFIRMATION NO. 1497

005487  
 ROSS J. OEHLER  
 AVENTIS PHARMACEUTICALS INC.  
 ROUTE 202-206  
 MAIL CODE: D303A  
 BRIDGEWATER, NJ 08807

## FILING RECEIPT



\*OC000000012479937\*

Date Mailed: 04/29/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Ronald Charles Bernotas, Bridgewater, NJ;  
 Paul Wayne Brown, Leawood, KS;  
 Gary Thomas Emmons, Washington, NJ;  
 Chi-Hsin Richard King, Slingerlands, NY;

**Assignment For Published Patent Application**

Aventis Pharmaceuticals Inc., Bridgewater, NJ;

**Domestic Priority data as claimed by applicant**

This application is a DIV of 10/200,821 07/22/2002 PAT 6,716,986  
 which is a DIV of 09/615,246 07/13/2000 PAT 6,465,490  
 which claims benefit of 60/198,215 07/16/1999 ABN

**Foreign Applications**

If Required, Foreign Filing License Granted: 04/28/2004

Projected Publication Date: 08/05/2004

Non-Publication Request: No

Early Publication Request: No

**Title**

A Method for the isolation of sulfuric acid mono-[3((1-[2-(4-fluorophenyl)-ethyl]-piperidin-4-yl)-2-methoxy-phenyl]ester  
 $\text{Ph}_2\text{C}(\text{O})\text{O}-\text{CH}_2-\text{CH}_2-\text{Ph}$ )

**Preliminary Class**

546

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).